Naitive Technologies and Parvizi Surgical Innovation partnered to advance the development and deployment of OsteoSight, an artificial intelligence tool for the early identification of low bone mineral density.
OsteoSight uses AI to scan millions of x-rays for low bone mineral density, an early warning sign of osteoporosis, according to a Nov. 7 news release. The technology earned FDA breakthrough device designation in 2023.
"With PSI's support, we're ensuring our technology meets the rigorous standards of clinical care but also seamlessly integrates into real-world orthopedic workflows," Will Briggs, MD, PhD, CEO of Naitive, said in the release. "Their leadership in musculoskeletal care, combined with our breakthrough technology, will help us make significant advancements in the early diagnosis and treatment of osteoporosis."
Naitive is a venture capital-backed group that specializes in digital technologies to support musculoskeletal health. Parvizi Surgical Innovation was founded in 2018 by Javad Parvizi, MD.